Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Indian Pediatr ; 1995 Aug; 32(8): 855-61
Article in English | IMSEAR | ID: sea-9827

ABSTRACT

OBJECTIVES: To assess efficacy and safety of oral iron chelating agent deferiprone (DFP) in patients with beta thalassemia and hemoglobin E-beta thalassemia. DESIGN: Non-randomized study. SETTING: Hematology Out-Patient Department. SUBJECTS: Forty-one patients of beta thalassemia and hemoglobin E-beta thalassemia. INTERVENTIONS: DFP was given to 20 patients, 10 patients of beta thalassemia and 10 with hemoglobin E-beta thalassemia; the rest were taken as controls. RESULTS: A significant fall in serum ferritin was observed in the study group along with rise in urinary iron excretion (p < 0.05). Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient. All these complications could be managed easily with medical supervision and no death or permanent disability was seen. CONCLUSIONS: DFP is an effective and fairly well tolerated oral iron chelating agent. The side effects that occur can be tackled easily if monitored properly.


Subject(s)
Administration, Oral , Adolescent , Adult , Chelating Agents/therapeutic use , Child , Child, Preschool , Female , Hemoglobin E/drug effects , Humans , India , Iron/blood , Male , Patient Compliance , Pyridones/administration & dosage , beta-Thalassemia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL